304 related articles for article (PubMed ID: 25092615)
1. Low-dose recombinant factor VIIa for reversing coagulopathy in patients with isolated traumatic brain injury.
Yuan Q; Wu X; Du ZY; Sun YR; Yu J; Li ZQ; Wu XH; Mao Y; Zhou LF; Hu J
J Crit Care; 2015 Feb; 30(1):116-20. PubMed ID: 25092615
[TBL] [Abstract][Full Text] [Related]
2. Reversal of coagulopathy in critically ill patients with traumatic brain injury: recombinant factor VIIa is more cost-effective than plasma.
Stein DM; Dutton RP; Kramer ME; Scalea TM
J Trauma; 2009 Jan; 66(1):63-72; discussion 73-5. PubMed ID: 19131807
[TBL] [Abstract][Full Text] [Related]
3. Recombinant factor VIIa: decreasing time to intervention in coagulopathic patients with severe traumatic brain injury.
Stein DM; Dutton RP; Kramer ME; Handley C; Scalea TM
J Trauma; 2008 Mar; 64(3):620-7; discussion 627-8. PubMed ID: 18332801
[TBL] [Abstract][Full Text] [Related]
4. [Role of small-dose recombinant human coagulation factor VIIa for coagulopathy in patients with isolated traumatic brain injury].
Pei BB; Li CY; Lu X; Wu X; Gao L; Yu J; Wu XH; Jin Y; Sun YR; Du ZY; Mao Y; Hu J; Zhou LF
Zhonghua Yi Xue Za Zhi; 2013 Jun; 93(23):1780-3. PubMed ID: 24124708
[TBL] [Abstract][Full Text] [Related]
5. Recombinant factor VIIa for the correction of coagulopathy before emergent craniotomy in blunt trauma patients.
Brown CV; Foulkrod KH; Lopez D; Stokes J; Villareal J; Foarde K; Curry E; Coopwood B
J Trauma; 2010 Feb; 68(2):348-52. PubMed ID: 20154547
[TBL] [Abstract][Full Text] [Related]
6. Prothrombin complex concentrate: an effective therapy in reversing the coagulopathy of traumatic brain injury.
Joseph B; Hadjizacharia P; Aziz H; Kulvatunyou N; Tang A; Pandit V; Wynne J; O'Keeffe T; Friese RS; Rhee P
J Trauma Acute Care Surg; 2013 Jan; 74(1):248-53. PubMed ID: 23271101
[TBL] [Abstract][Full Text] [Related]
7. The use of recombinant activated factor VIIa in coagulopathic traumatic brain injuries requiring emergent craniotomy: is it beneficial?
McQuay N; Cipolla J; Franges EZ; Thompson GE
J Neurosurg; 2009 Oct; 111(4):666-71. PubMed ID: 19425887
[TBL] [Abstract][Full Text] [Related]
8. Recombinant factor VIIa to correct coagulopathy in patients with traumatic brain injury presenting to outlying facilities before transfer to the regional trauma center.
Brown CV; Sowery L; Curry E; Valadka AB; Glover CS; Grabarkewitz K; Green T; Hail S; Admire J
Am Surg; 2012 Jan; 78(1):57-60. PubMed ID: 22273315
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Fresh-Frozen Plasma, Four-Factor Prothrombin Complex Concentrates, and Recombinant Factor VIIa to Facilitate Procedures in Critically Ill Patients with Coagulopathy from Liver Disease: A Retrospective Cohort Study.
Kwon JO; MacLaren R
Pharmacotherapy; 2016 Oct; 36(10):1047-1054. PubMed ID: 27547916
[TBL] [Abstract][Full Text] [Related]
10. Low-dose recombinant factor VIIa for trauma patients with coagulopathy.
Stein DM; Dutton RP; Hess JR; Scalea TM
Injury; 2008 Sep; 39(9):1054-61. PubMed ID: 18656871
[TBL] [Abstract][Full Text] [Related]
11. Early versus late recombinant factor VIIa in combat trauma patients requiring massive transfusion.
Perkins JG; Schreiber MA; Wade CE; Holcomb JB
J Trauma; 2007 May; 62(5):1095-9; discussion 1099-101. PubMed ID: 17495707
[TBL] [Abstract][Full Text] [Related]
12. Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy.
Shami VM; Caldwell SH; Hespenheide EE; Arseneau KO; Bickston SJ; Macik BG
Liver Transpl; 2003 Feb; 9(2):138-43. PubMed ID: 12548507
[TBL] [Abstract][Full Text] [Related]
13. Recombinant activated factor VII use in critically ill patients: clinical outcomes and thromboembolic events.
Brophy GM; Candeloro CL; Robles JR; Brophy DF
Ann Pharmacother; 2013 Apr; 47(4):447-54. PubMed ID: 23535812
[TBL] [Abstract][Full Text] [Related]
14. Coagulopathic patients with traumatic intracranial bleeding: defining the role of recombinant factor VIIa.
Bartal C; Freedman J; Bowman K; Cusimano M
J Trauma; 2007 Oct; 63(4):725-32. PubMed ID: 18089997
[TBL] [Abstract][Full Text] [Related]
15. Ability of Fibrin Monomers to Predict Progressive Hemorrhagic Injury in Patients with Severe Traumatic Brain Injury.
Esnault P; Mathais Q; D'Aranda E; Montcriol A; Cardinale M; Cungi PJ; Goutorbe P; Joubert C; Dagain A; Meaudre E
Neurocrit Care; 2020 Aug; 33(1):182-195. PubMed ID: 31797276
[TBL] [Abstract][Full Text] [Related]
16. Coagulopathy in severe traumatic brain injury: a prospective study.
Talving P; Benfield R; Hadjizacharia P; Inaba K; Chan LS; Demetriades D
J Trauma; 2009 Jan; 66(1):55-61; discussion 61-2. PubMed ID: 19131806
[TBL] [Abstract][Full Text] [Related]
17. Treatment of refractory bleeding after cardiac operations with low-dose recombinant activated factor VII (NovoSeven): a propensity score analysis.
Gelsomino S; Lorusso R; Romagnoli S; Bevilacqua S; De Cicco G; Billè G; Stefàno P; Gensini GF
Eur J Cardiothorac Surg; 2008 Jan; 33(1):64-71. PubMed ID: 17996457
[TBL] [Abstract][Full Text] [Related]
18. Intraoperative use of low-dose recombinant activated factor VII during thoracic aortic operations.
Andersen ND; Bhattacharya SD; Williams JB; Fosbol EL; Lockhart EL; Patel MB; Gaca JG; Welsby IJ; Hughes GC
Ann Thorac Surg; 2012 Jun; 93(6):1921-8; discussion 1928-9. PubMed ID: 22551846
[TBL] [Abstract][Full Text] [Related]
19. Recombinant factor VIIa (NovoSeven RT) use in high risk cardiac surgery.
Chapman AJ; Blount AL; Davis AT; Hooker RL
Eur J Cardiothorac Surg; 2011 Dec; 40(6):1314-8; discussion 1318-9. PubMed ID: 21601468
[TBL] [Abstract][Full Text] [Related]
20. Recombinant factor VIIa: unregulated continuous use in patients with bleeding and coagulopathy does not alter mortality and outcome.
Ganguly S; Spengel K; Tilzer LL; O'neal B; Simpson SQ
Clin Lab Haematol; 2006 Oct; 28(5):309-12. PubMed ID: 16999720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
